Bioextrax (BIOEX) Q4 2025 earnings summary

Executive summary

• Advanced key projects, including new partnerships and technology development, strengthening long-term positioning.

• Signed significant agreements, including MoUs and collaborations with major industry players for PHA and protein applications.

• Focused on process optimization, reducing PHBV accumulation time by 20%, improving capital efficiency.

Financial highlights

• Net sales for Q4 2025 were 3 tkr (122 tkr Q4 2024); full year 2025 net sales reached 757 tkr (515 tkr 2024).

• Operating loss for Q4 2025 was -5,050 tkr (-4,088 tkr Q4 2024); full year operating loss was -17,839 tkr (-17,539 tkr 2024).

• Net result per share for 2025 was -0.45 SEK (-0.52 SEK 2024); Q4 2025 was -0.13 SEK (-0.11 SEK Q4 2024).

• Cash flow for 2025 was -13,336 tkr (3,868 tkr 2024); cash and cash equivalents at year-end were 3,931 tkr (17,267 tkr 2024).

• Equity per share at year-end was 0.53 SEK (0.67 SEK 2024); equity ratio was 85.79% (89.87% 2024).

Outlook and guidance

• Ongoing commercialization efforts with several potential customers and partners through commercial license agreements.

• Board assesses liquidity, after a rights issue of 13.3 MSEK, as sufficient for the next twelve months.